Pulse Biosciences (PLSE) Canaccord Genuity's 46th Annual Growth Conference summary

Leadership and management experience

• CEO has over 30 years in med tech, including leadership at major firms and extensive VC experience.

• Board and management include veterans from Computer Motion and other successful med tech ventures.

• Major shareholder is a proven entrepreneur with a history of building and selling high-value companies.

• Key executives have deep expertise in technology, clinical operations, and R&D.

• Strong team culture and execution focus highlighted as core strengths.

Technology and innovation

• Nanosecond Pulsed Field Ablation (nsPFA) is a next-generation, non-thermal ablation technology.

• nsPFA enables precise, minimally invasive tissue ablation with reduced inflammatory response.

• Technology is protected by 250 patents and years of development.

• First major application targets atrial fibrillation (AFib), a large and growing market.

• nsPFA offers unique biological effects and can be used near sensitive structures.

Clinical development and trial progress

• Nano-Pulse AF trial is enrolling rapidly, driven by physician enthusiasm and strong European feasibility data.

• European study showed a reduction in AFib failure rates from 25% to 4%.

• Procedure time and number of ablations are significantly reduced compared to existing technologies.

• U.S. pivotal trial closely mirrors successful European protocols to ensure data transferability.

• Minor protocol changes and patient additions were made with FDA approval to reflect real-world practice.